Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3274 - Impact of the biological subtype on the risk of developing brain metastasis in Egyptian breast cancer patients

Date

10 Oct 2016

Session

Poster display

Presenters

Loay Kassem

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

L. Kassem1, R. Abdel-Malek1, D. Abd El Moneim2, M. Ismail2, H.A. Azim3

Author affiliations

  • 1 Clinical Oncology, Cairo University, 35855 - Cairo/EG
  • 2 Medical Oncology, Cairo oncology center (Cairocure), 12311 - Cairo/EG
  • 3 Clinical Oncology Department, Cairo University, Cairo/EG
More

Resources

Abstract 3274

Background

We aimed at investigating the impact of the biological subtype of breast cancer on the risk of developing brain metastasis and the outcome of Egyptian patients with brain metastasis.

Methods

We retrospectively reviewed the clinical records of 2193 consecutive women (1947 with localized disease and 246 with metastatic disease at presentation) diagnosed with breast cancer between January 1999 and December 2010. We explored the relationship between the clinico-pathological factors (including the biological subtypes) and the incidence of brain metastasis, Brain metastasis free survival (BMFS), and the Brain metastasis specific survival (BMSS).

Results

Median follow up period for the whole cohort was 43.5 months (IQR 26-74 months); 160 patients (7.3%) developed brain metastasis. Among the individual clinico-pathological parameters, larger tumors (p = 0.006), axillary LN positivity (p 

Conclusions

Breast cancer biological subtype plays a pivotal role in predicting the pattern of failure of patients presenting with localized disease and the subsequent outcome after brain metastasis in addition to the classical prognostic factors.

Clinical trial identification

Legal entity responsible for the study

Cairo Oncology Center

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings